



Ajinomoto Bio-Pharma expands manufacturing agreement with AstraZeneca

31 March 2021 | News

Partnership expands to include drug product manufacturing



Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services with sites in Belgium, United States, Japan, and India, has announced the manufacturing agreement expansion with AstraZeneca to include drug product manufacturing.

This agreement expands the scope of Aji Bio-Pharma's service offerings to AstraZeneca to include aseptic fill-finish services at its San Diego, California facility, in addition to small-molecule manufacturing services proceeding in Belgium.

"We are excited to expand our manufacturing agreement with AstraZeneca and to support them with additional service offerings," said Magnus Busch, Global Account Manager, Ajinomoto Bio-Pharma Services. "Our San Diego team is proud to join our Belgium colleagues in support of AstraZeneca. This expanded agreement builds on our commitment to be a leading, trusted, innovative partner to our clients."